History

April 27, 2006

23andMe founded

May 22, 2007

Series A financing

March 12, 2009

Parkinson’s disease research initiative launched

June 15, 2011

23andMe database surpasses 100,000 customers

August 17, 2011

Replication of more than 180 genetic associations, proving efficacy of 23andMe web-based research model

November 22, 2013

23andMe receives an FDA warning letter stating health-related reports must go through FDA review process

November 19, 2007

23andMe launches first product at $999

October 13, 2009

23andMe tests NFL players’ DNA for athletic genetic factors

June 23, 2011

23andMe identifies two new genetic associations with Parkinson’s disease and finds a substantial genetic component for the disease

March 14, 2013

Identified multiple genetic factors impacting development of nearsightedness in largest ever genome-wide association study on myopia

May 29, 2008

Launch of consumer-enabled research program to actively engage individuals in genetics research

April 23, 2010

DNA Day 2010 promotion offers $99 experimental price drop; inventory sells out

July 3, 2012

23andMe contributes to genetic discoveries related to breast size and breast cancer

December 4, 2012

23andMe Scientists receive more than $500,000 in funding from the National Institutes of Health in support of projects to better understand the genetics of allergies; to assess accuracy of new sequencing technologies in clinical applications; and to develop tools that will further accelerate the pace of human genetic research

December 11, 2012

Series D financing raises more than $50 million; reduces price to $99

January 28, 2014

23andMe helps identify 11 new genetic associations for asthma-with-hay fever

February 4, 2015

23andMe study uncovers the genetics of motion sickness

January 2015

Collaborations with Genentech and Pfizer to study disease

March 3, 2015

Researchers from Stanford University and 23andMe discover genetic links to Rosacea

February 19, 2015

23andMe receives first ever FDA authorization for a direct-to- consumer genetic test:

carrier status report for Bloom’s syndrome, clearing way for similar tests

October 14, 2015

Series E financing raises $115 million

June 18, 2015

23andMe surpasses 1 million genotyped customers

October 21, 2015

New customer experience launches for $199, includes first health-related reports meeting FDA requirements

Feb 2, 2016

23andMe study publishes in Nature which identifies genetic variants associated with preference to mornings or nights

Feb 22, 2017

Celmatix and 23andMe announce launch of fertility research community; 5,000 people enroll within 10 days

April 6, 2017

Granted first ever FDA authorization to market direct-to-consumer Genetic Health Risk reports, including tests for Alzheimer’s and Parkinson’s disease.

April 2017

23andMe surpasses 2 million genotyped customers

March 21, 2016

23andMe announces a new Apple ResearchKit module that allows researchers to integrate genetic information into app-based studies

April 5, 2016

$250,000 NIH grant funds 23andMe research leveraging genetic ancestry to uncover variants associated with disease

September 21, 2016

23andMe offers a genetic ancestry only service as a standalone product for $99

October 13, 2016

NIH grant  to reduce health research disparities among African Americans

October 19, 2016

23andMe launches genotyping services for research grant program

April 2015

Additional international launches (Denmark, Finland, Ireland, Netherlands, Sweden)

March 2015

Therapeutics Group forms, led by esteemed scientist, Richard Scheller

October 2014

23andMe launches health reports in Canada

December 2014

23andMe launches health reports in UK

June 24, 2010

23andMe makes new genetic discoveries for hair curl, asparagus anosmia, the photic sneeze reflex, and freckling using web-based, participant-driven methods

November 9, 2010

Series C financing raises more than $22 million

October 30, 2008

TIME Magazine names 23andMe’s PGS 2008 Invention of the Year

Sept 9, 2008

23andMe price reduced to $399